Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Light quality characterization under climate screens and shade nets for controlled-environment agriculture.

Kotilainen T, Robson TM, Hernández R.

PLoS One. 2018 Jun 25;13(6):e0199628. doi: 10.1371/journal.pone.0199628. eCollection 2018.

2.

Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer.

McCrudden CM, McBride JW, McCaffrey J, McErlean EM, Dunne NJ, Kett VL, Coulter JA, Robson T, McCarthy HO.

Cancer Nanotechnol. 2018;9(1):5. doi: 10.1186/s12645-018-0040-x. Epub 2018 Jun 1.

3.

Do UV-A radiation and blue light during growth prime leaves to cope with acute high-light in photoreceptor mutants of Arabidopsis thaliana?

Brelsford CC, Morales LO, Nezval J, Kotilainen TK, Hartikainen SM, Aphalo PJ, Robson TM.

Physiol Plant. 2018 Apr 28. doi: 10.1111/ppl.12749. [Epub ahead of print]

PMID:
29704249
4.

DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system.

Cole G, Ali AA, McCrudden CM, McBride JW, McCaffrey J, Robson T, Kett VL, Dunne NJ, Donnelly RF, McCarthy HO.

Eur J Pharm Biopharm. 2018 Jun;127:288-297. doi: 10.1016/j.ejpb.2018.02.029. Epub 2018 Mar 3.

PMID:
29510205
5.

BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.

Byrne T, Nelson L, Beirne JP, Sharpe D, Quinn JE, McCluggage WG, Robson T, Furlong F.

Int J Gynecol Cancer. 2018 Mar;28(3):472-478. doi: 10.1097/IGC.0000000000001214.

PMID:
29465507
6.

Targeting cancer stem cells in the clinic: Current status and perspectives.

Annett S, Robson T.

Pharmacol Ther. 2018 Jul;187:13-30. doi: 10.1016/j.pharmthera.2018.02.001. Epub 2018 Feb 5. Review.

PMID:
29421575
7.

Environmental effects of ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2017.

Bais AF, Lucas RM, Bornman JF, Williamson CE, Sulzberger B, Austin AT, Wilson SR, Andrady AL, Bernhard G, McKenzie RL, Aucamp PJ, Madronich S, Neale RE, Yazar S, Young AR, de Gruijl FR, Norval M, Takizawa Y, Barnes PW, Robson TM, Robinson SA, Ballaré CL, Flint SD, Neale PJ, Hylander S, Rose KC, Wängberg SÅ, Häder DP, Worrest RC, Zepp RG, Paul ND, Cory RM, Solomon KR, Longstreth J, Pandey KK, Redhwi HH, Torikai A, Heikkilä AM.

Photochem Photobiol Sci. 2018 Feb 14;17(2):127-179. doi: 10.1039/c7pp90043k.

PMID:
29404558
8.

Emerging Roles for von Willebrand Factor in Cancer Cell Biology.

O'Sullivan JM, Preston RJS, Robson T, O'Donnell JS.

Semin Thromb Hemost. 2018 Mar;44(2):159-166. doi: 10.1055/s-0037-1607352. Epub 2017 Nov 17.

PMID:
29165741
9.

Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment.

McCrudden CM, McBride JW, McCaffrey J, Ali AA, Dunne NJ, Kett VL, Coulter JA, Robson T, McCarthy HO.

Mol Ther Nucleic Acids. 2017 Mar 17;6:249-258. doi: 10.1016/j.omtn.2016.12.010. Epub 2016 Dec 31.

10.

DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles.

Ali AA, McCrudden CM, McCaffrey J, McBride JW, Cole G, Dunne NJ, Robson T, Kissenpfennig A, Donnelly RF, McCarthy HO.

Nanomedicine. 2017 Apr;13(3):921-932. doi: 10.1016/j.nano.2016.11.019. Epub 2016 Dec 12.

PMID:
27979747
11.

Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.

Massey AS, Pentlavalli S, Cunningham R, McCrudden CM, McErlean EM, Redpath P, Ali AA, Annett S, McBride JW, McCaffrey J, Robson T, Migaud ME, McCarthy HO.

Mol Pharm. 2016 Apr 4;13(4):1217-28. doi: 10.1021/acs.molpharmaceut.5b00670. Epub 2016 Mar 22.

PMID:
26954700
12.

Excessive sulphur accumulation and ionic storage behaviour identified in species of Acacia (Leguminosae: Mimosoideae).

Reid N, Robson TC, Radcliffe B, Verrall M.

Ann Bot. 2016 Apr;117(4):653-66. doi: 10.1093/aob/mcw009. Epub 2016 Mar 5.

13.

Transcending epithelial and intracellular biological barriers; a prototype DNA delivery device.

McCaffrey J, McCrudden CM, Ali AA, Massey AS, McBride JW, McCrudden MT, Vicente-Perez EM, Coulter JA, Robson T, Donnelly RF, McCarthy HO.

J Control Release. 2016 Mar 28;226:238-47. doi: 10.1016/j.jconrel.2016.02.023. Epub 2016 Feb 13.

PMID:
26883753
14.

Development of TMTP-1 targeted designer biopolymers for gene delivery to prostate cancer.

McBride JW, Massey AS, McCaffrey J, McCrudden CM, Coulter JA, Dunne NJ, Robson T, McCarthy HO.

Int J Pharm. 2016 Mar 16;500(1-2):144-53. doi: 10.1016/j.ijpharm.2016.01.039. Epub 2016 Jan 21.

PMID:
26802497
15.

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, Ward GA, Chessari G, Johnson C, Crawford NT, LaBonte MJ, Prise KM, Robson T, Salto-Tellez M, Longley DB, Waugh DJ.

Oncotarget. 2016 Feb 16;7(7):7885-98. doi: 10.18632/oncotarget.6955.

16.

Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.

Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ.

Cancer. 2016 Mar 1;122(5):664-73. doi: 10.1002/cncr.29814. Epub 2015 Dec 22. No abstract available.

17.

Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.

Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, Collins B, Robson T, Scorfield S, Green K, Hall C, Liao XH, Ryan M, Johnson F, Stevens G, Kearins O, Sellars S, Patnick J.

Lancet Oncol. 2016 Jan;17(1):109-14. doi: 10.1016/S1470-2045(15)00446-5. Epub 2015 Dec 5. Erratum in: Lancet Oncol. 2016 Feb;17(2):e46.

18.

RALA-mediated delivery of FKBPL nucleic acid therapeutics.

Bennett R, Yakkundi A, McKeen HD, McClements L, McKeogh TJ, McCrudden CM, Arthur K, Robson T, McCarthy HO.

Nanomedicine (Lond). 2015 Oct;10(19):2989-3001. doi: 10.2217/nnm.15.115. Epub 2015 Sep 30.

19.

The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases.

McClements L, Annett S, Yakkundi A, Robson T.

Curr Mol Pharmacol. 2015;9(2):165-79.

PMID:
25986561
20.

FKBPL: a marker of good prognosis in breast cancer.

Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T.

Oncotarget. 2015 May 20;6(14):12209-23.

21.

The varying influence of socioeconomic deprivation on breast cancer screening uptake in London.

Jack RH, Robson T, Davies EA.

J Public Health (Oxf). 2016 Jun;38(2):330-4. doi: 10.1093/pubmed/fdv038. Epub 2015 Mar 31.

PMID:
25829530
22.

FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.

Yakkundi A, Bennett R, Hernández-Negrete I, Delalande JM, Hanna M, Lyubomska O, Arthur K, Short A, McKeen H, Nelson L, McCrudden CM, McNally R, McClements L, McCarthy HO, Burns AJ, Bicknell R, Kissenpfennig A, Robson T.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):845-54. doi: 10.1161/ATVBAHA.114.304539. Epub 2015 Mar 12.

23.

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T.

PLoS One. 2015 Feb 17;10(2):e0118187. doi: 10.1371/journal.pone.0118187. eCollection 2015.

24.

Ultraviolet and photosynthetically active radiation can both induce photoprotective capacity allowing barley to overcome high radiation stress.

Klem K, Holub P, Štroch M, Nezval J, Špunda V, Tříska J, Jansen MA, Robson TM, Urban O.

Plant Physiol Biochem. 2015 Aug;93:74-83. doi: 10.1016/j.plaphy.2015.01.001. Epub 2015 Jan 7.

PMID:
25583309
25.

Breast cancer screening uptake among women from different ethnic groups in London: a population-based cohort study.

Jack RH, Møller H, Robson T, Davies EA.

BMJ Open. 2014 Oct 16;4(10):e005586. doi: 10.1136/bmjopen-2014-005586.

26.

Lead by actions, not your job title.

Robson T.

Nurs Times. 2014 Jun 25-Jul 1;110(26):33. No abstract available.

PMID:
25204026
27.

Are you making the most of your time?

Robson T.

Nurs Times. 2014 Jul 9-15;110(28):33. No abstract available.

PMID:
25087445
28.

How does solar ultraviolet-B radiation improve drought tolerance of silver birch (Betula pendula Roth.) seedlings?

Robson TM, Hartikainen SM, Aphalo PJ.

Plant Cell Environ. 2015 May;38(5):953-67. doi: 10.1111/pce.12405. Epub 2014 Aug 13.

29.

Epidermal UV-A absorbance and whole-leaf flavonoid composition in pea respond more to solar blue light than to solar UV radiation.

Siipola SM, Kotilainen T, Sipari N, Morales LO, Lindfors AV, Robson TM, Aphalo PJ.

Plant Cell Environ. 2015 May;38(5):941-52. doi: 10.1111/pce.12403. Epub 2014 Aug 13.

30.

Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery.

McCarthy HO, McCaffrey J, McCrudden CM, Zholobenko A, Ali AA, McBride JW, Massey AS, Pentlavalli S, Chen KH, Cole G, Loughran SP, Dunne NJ, Donnelly RF, Kett VL, Robson T.

J Control Release. 2014 Sep 10;189:141-9. doi: 10.1016/j.jconrel.2014.06.048. Epub 2014 Jul 1.

PMID:
24995949
31.

Re-interpreting plant morphological responses to UV-B radiation.

Robson TM, Klem K, Urban O, Jansen MA.

Plant Cell Environ. 2015 May;38(5):856-66. doi: 10.1111/pce.12374. Epub 2014 Jun 24. Review.

32.

Cadmium contamination of agricultural soils and crops resulting from sphalerite weathering.

Robson TC, Braungardt CB, Rieuwerts J, Worsfold P.

Environ Pollut. 2014 Jan;184:283-9. doi: 10.1016/j.envpol.2013.09.001. Epub 2013 Sep 25.

PMID:
24077256
33.

Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.

Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A, Prise KM, McCarthy HO, Robson T.

Oncogene. 2014 Jun 26;33(26):3441-50. doi: 10.1038/onc.2013.306. Epub 2013 Aug 5.

PMID:
23912458
34.

Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.

McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T.

Clin Cancer Res. 2013 Jul 15;19(14):3881-93. doi: 10.1158/1078-0432.CCR-13-0595. Epub 2013 Jun 5.

35.

The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.

Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG, Robson T.

PLoS One. 2013;8(2):e55075. doi: 10.1371/journal.pone.0055075. Epub 2013 Feb 15.

36.

The contribution of N₂O₃ to the cytotoxicity of the nitric oxide donor DETA/NO: an emerging role for S-nitrosylation.

Ali AA, Coulter JA, Ogle CH, Migaud MM, Hirst DG, Robson T, McCarthy HO.

Biosci Rep. 2013 Mar 28;33(2). pii: e00031. doi: 10.1042/BSR20120120.

37.

Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21(WAF1/CIP1) promoter.

McCluskey AG, Mairs RJ, Sorensen A, Robson T, McCarthy HO, Pimlott SL, Babich JW, Champion S, Boyd M.

Radiat Res. 2013 Mar;179(3):282-92. doi: 10.1667/RR3030.1. Epub 2013 Jan 21.

PMID:
23336184
38.

DNA repair and replication proteins as prognostic markers in melanoma.

Song L, Robson T, Doig T, Brenn T, Mathers M, Brown ER, Doherty V, Bartlett JM, Anderson N, Melton DW.

Histopathology. 2013 Jan;62(2):343-50. doi: 10.1111/j.1365-2559.2012.04362.x. Epub 2012 Sep 28.

PMID:
23020778
39.

Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.

van de Water W, Fontein DB, van Nes JG, Bartlett JM, Hille ET, Putter H, Robson T, Liefers GJ, Roumen RM, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JW, van de Velde CJ.

Eur J Cancer. 2013 Jan;49(2):297-304. doi: 10.1016/j.ejca.2012.07.026. Epub 2012 Sep 3.

40.

The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein.

Robson T, James IF.

Drug Discov Today. 2012 Jun;17(11-12):544-8. doi: 10.1016/j.drudis.2012.01.002. Epub 2012 Jan 16. Review.

PMID:
22265918
41.

Species-specific effect of UV-B radiation on the temporal pattern of leaf growth.

Robson TM, Aphalo PJ.

Physiol Plant. 2012 Feb;144(2):146-60. doi: 10.1111/j.1399-3054.2011.01546.x. Epub 2012 Jan 9.

PMID:
22224454
42.

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.

Bartlett AI, Starcyznski J, Robson T, Maclellan A, Campbell FM, van de Velde CJ, Hasenburg A, Markopoulos C, Seynaeve C, Rea D, Bartlett JM.

Am J Clin Pathol. 2011 Aug;136(2):266-74. doi: 10.1309/AJCP0EN6AQMWETZZ.

PMID:
21757600
43.

The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL.

McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne C, Yakkundi A, McCarthy HO, Gallagher WM, Robson T.

Biochem Soc Trans. 2011 Apr;39(2):663-8. doi: 10.1042/BST0390663. Review.

PMID:
21428958
44.

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D.

J Clin Oncol. 2011 Apr 20;29(12):1531-8. doi: 10.1200/JCO.2010.30.3677. Epub 2011 Mar 21.

45.

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T.

Clin Cancer Res. 2011 Mar 1;17(5):1044-56. doi: 10.1158/1078-0432.CCR-10-2241. Epub 2011 Mar 1.

46.

Nitric oxide physiology and pathology.

Hirst DG, Robson T.

Methods Mol Biol. 2011;704:1-13. doi: 10.1007/978-1-61737-964-2_1. Review.

PMID:
21161625
47.

Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy.

McCarthy HO, Zholobenko AV, Wang Y, Canine B, Robson T, Hirst DG, Hatefi A.

Int J Pharm. 2011 Feb 28;405(1-2):196-202. doi: 10.1016/j.ijpharm.2010.11.051. Epub 2010 Dec 4.

PMID:
21134429
48.

Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.

Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO.

J Gene Med. 2010 Sep;12(9):755-65. doi: 10.1002/jgm.1495.

PMID:
20821746
49.

Molecular biology: the key to personalised treatment in radiation oncology?

Hirst DG, Robson T.

Br J Radiol. 2010 Sep;83(993):723-8. doi: 10.1259/bjr/91488645.

50.

Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice.

Musson JA, Ingram R, Durand G, Ascough S, Waters EL, Hartley MG, Robson T, Maillere B, Williamson ED, Sriskandan S, Altmann D, Robinson JH.

Infect Immun. 2010 Oct;78(10):4356-62. doi: 10.1128/IAI.00195-10. Epub 2010 Jul 26.

Supplemental Content

Loading ...
Support Center